{
    "Clinical Trial ID": "NCT00853996",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Prevention (Acolbifene Hydrochloride)",
        "  Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.",
        "  acolbifene hydrochloride: Given orally"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Gail risk >= 1.7% and/or relative risk >= 3 times that for 5-year age group",
        "  Premenopausal",
        "  More than 6 months since initiating or discontinuing oral contraceptives",
        "  At increased risk for breast cancer, as indicated by >= 1 of the following risk factors:",
        "  BRCA1/2 mutation characterized as deleterious or of uncertain significance",
        "  Prior atypical ductal hyperplasia, ductal carcinoma in situ, or lobular carcinoma in situ",
        "  Prior random periareolar fine needle aspiration (RPFNA) showing atypical hyperplasia",
        "  Family history consistent with hereditary breast cancer, as indicated by 1 of the following criteria:",
        "  >= 4 relatives with breast cancer",
        "  >= 2 relatives diagnosed with breast cancer at  50 years of age",
        "  Breast and ovarian cancer diagnosed in same relative",
        "  No suspicion for breast cancer on baseline mammogram performed between days 1-10 of menstrual cycle within 3 months prior to screening baseline RPFNA",
        "  Exhibits hyperplasia with or without atypia (Masood score >= 14) with >= 500 cells AND Ki-67 positivity >= 2% by RPFNA performed within 6 months prior to initiation of study drug",
        "  Estimated visual mammographic breast density category >= 5% on mammogram performed within 6 months prior to initiation of study drug",
        "  Has regular menstrual cycles (between 21 and 35 days) unless using extended regimen oral contraceptives or a contraceptive device (e.g., Mirena IUD) Values for metabolic profile and blood count within normal limits",
        "  Absolute granulocyte count > 1,000/mm^3",
        "  Platelets > 100,000/mm^3",
        "  Hemoglobin > 10 g/dL",
        "  Bilirubin < 2.0 mg/dL",
        "  AST < 2 times upper limit of normal (ULN)",
        "  Albumin > 3.0 g/dL",
        "  Creatinine < 1.5 mg/dL",
        "  Alkaline phosphatase < 2 times ULN",
        "  Concurrent hormonal contraceptives allowed provided patient remains on the same hormonal regimen from 3 months prior to baseline aspiration until the completion of study treatment",
        "  Fertile patients must use effective contraception during and for 3 months after completion of study treatment",
        "  Willing to ingest recommended dose of calcium and vitamin D for premenopausal bone health (1,200 mg calcium and 800 IU vitamin D daily)",
        "  Negative pregnancy test prior to receiving study agent",
        "  Exclusion Criteria",
        "  pregnant or nursing",
        "  nursing within the past 6 months",
        "  Known osteoporosis or severe osteopenia (T-score -2 or worse by DEXA)",
        "  History of symptomatic endometriosis with pelvic pain, poorly controlled migraines, or hot flashes",
        "  History of deep venous thrombosis",
        "  History of allergic reactions attributed to compounds of similar chemical or biological composition to the study agent",
        "  Other condition or concurrent illness that, in the opinion of the investigator, would make the patient a poor candidate for RPFNA",
        "  Less than 1 year since prior use of aromatase inhibitors (e.g., anastrozole, exemestane, or letrozole) or selective estrogen receptor modulators (e.g., tamoxifen citrate, raloxifene, or arzoxifene hydrochloride)",
        "  Other concurrent chemopreventive agents",
        "  Concurrent anticoagulants",
        "  Other concurrent investigational agents",
        "  Bilateral breast implants"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Change in the Percentage of Breast Epithelial Cells Expressing Ki-67, From Baseline to 6 Months",
        "  Change in proliferation as measured by Ki-67 immunocytochemical expression in breast epithelial cells obtained by random periareolar fine needle aspiration at baseline and at 6 months.",
        "  Time frame: Baseline to 6 months",
        "Results 1: ",
        "  Arm/Group Title: Prevention (Acolbifene Hydrochloride)",
        "  Arm/Group Description: Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.",
        "  acolbifene hydrochloride: Given orally",
        "  Overall Number of Participants Analyzed: 25",
        "  Median (Inter-Quartile Range)",
        "  Unit of Measure: percentage of positive cells  -3.0        (-20.2 to 2.8)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/25 (0.00%)"
    ]
}